Enhancing Patient Selection in Oncology: Clinical Validation of a Multi-Gene Expression Diagnostic

Time: 2:15 pm
day: Day Three Track B

Details:

  •  Introduction to Allarity’s Drug Response Predictor (DRP)- a multi-gene expression diagnostic for selecting patients likely to benefit from cancer therapies
  • Key findings from the phase II ddvanced, recurrent ovarian cancer study showcasing the impact of Allarity’s novel PARP/ Tankyrase inhibitor, Stenoparib
  • A discussion of Stenoparib’s potential in advanced ovarian cancer using the Stenoparib DRP to select patients for therapeutic benefit

Speakers: